$26.60
+0.87 (+3.38%)
Open$25.89
Previous Close$25.73
Day High$26.97
Day Low$25.89
52W High$40.65
52W Low$12.12
Volume—
Avg Volume1.86M
Market Cap1.73B
P/E Ratio—
EPS$-2.39
SectorBiotechnology
Analyst Ratings
Strong Buy
22 analysts
Price Target
-29.5% upside
Current
$26.60
$26.60
Target
$18.74
$18.74
$15.89
$18.74 avg
$31.24
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 572.13M | 572.72M | 559.98M |
| Net Income | -99,921,707 | -80,567,499 | -92,627,690 |
| Profit Margin | -17.5% | -14.1% | -16.5% |
| EBITDA | -119,066,634 | -104,548,216 | -110,415,827 |
| Free Cash Flow | -98,412,160 | -88,741,836 | -111,480,768 |
| Rev Growth | +16.0% | -4.7% | +5.4% |
| Debt/Equity | 0.49 | 0.55 | 0.51 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $264.48 | +0.20% | 74.0 | 466.74B |
| AMGN | Amgen Inc | $393.16 | +1.95% | 23.7 | 207.25B |
| GILD | Gilead Sciences Inc | $150.56 | +0.30% | — | 187.10B |
| VRTX | Vertex Pharmaceuticals Inc | $510.72 | +0.47% | 29.7 | 130.64B |
| REGN | Regeneron Pharmaceuticals | $798.17 | +1.70% | 18.6 | 80.58B |
| ALNY | Alnylam Pharmaceuticals Inc | $244.32 | +1.99% | 40.0 | 32.33B |